Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Sensipar
Generic Name
Cinacalcet Hydrochloride
Active Ingredient
CinacalcetCategory
Other
Salt Form
Hydrochloride
Variants
3
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Sensipar, you must consult a qualified healthcare professional.
Detailed information about Sensipar
Cinacalcet is a calcimimetic agent used to treat secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism.
The dosage of Cinacalcet must be highly individualized and titrated based on the patient's serum calcium and PTH levels. Healthcare providers typically start with a low dose and adjust it every 2 to 4 weeks.
Cinacalcet is generally not recommended for use in pediatric patients with CKD unless under the strict guidance of a pediatric nephrologist. In 2013, the FDA issued a safety communication following the death of a pediatric patient in a clinical trial, which was linked to severe hypocalcemia. While some formulations (granules) are approved for children aged 3 and older in specific jurisdictions (like the EU) for secondary HPT, its use in the United States remains largely restricted to adults. If prescribed for a child, the dose is based on body weight and must be monitored with extreme frequency.
No dosage adjustment of Cinacalcet is necessary for patients with renal impairment, as the drug is primarily used in patients already suffering from advanced kidney disease (Stage 5 CKD on dialysis).
In patients with moderate to severe hepatic impairment (liver disease), Cinacalcet exposure (AUC) can be 2 to 4 times higher than in patients with normal liver function. Healthcare providers will monitor these patients very closely, and dose titration may occur more slowly.
Clinical studies did not identify significant differences in safety or efficacy between patients over 65 and younger patients. However, since elderly patients are more likely to have decreased hepatic or cardiac function, the starting dose should be approached with caution.
To ensure the best results and minimize side effects, follow these guidelines:
If you miss a dose of Cinacalcet, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Never take two doses at once to make up for a missed one. If you miss several doses, contact your healthcare provider for instructions, as your calcium levels may need to be checked.
An overdose of Cinacalcet can lead to dangerously low levels of serum calcium (hypocalcemia). Symptoms of an overdose may include tingling in the fingers or toes, muscle aches, cramping, or seizures. In the event of a suspected overdose, seek emergency medical attention immediately. Treatment typically involves the administration of intravenous calcium and close cardiac monitoring.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to a rapid rebound in PTH and calcium levels.
Cinacalcet is known to cause gastrointestinal and mineral-related side effects in a significant portion of patients. The most frequently reported adverse reactions include:
Cinacalcet is a potent medication that significantly alters mineral metabolism. The most critical safety concern is the risk of hypocalcemia (low blood calcium). Because calcium is vital for muscle contraction, nerve signaling, and heart function, low levels can lead to life-threatening complications. Patients must be committed to regular blood monitoring as scheduled by their nephrologist or endocrinologist.
No FDA black box warnings for Cinacalcet. However, the clinical community treats the risk of hypocalcemia with a level of caution similar to a boxed warning, particularly regarding its use in children.
Cinacalcet lowers the threshold for seizures. Patients with a pre-existing history of seizure disorders are at a higher risk when taking this medication. If blood calcium levels drop significantly, even patients without a history of seizures may experience them. It is imperative that serum calcium is measured within one week of starting the drug or adjusting the dose.
While there are few absolute contraindications for drug combinations, Cinacalcet should not be used in combination with Etelcalcetide (Parsabiv), which is an intravenous calcimimetic. Using both together significantly increases the risk of severe, life-threatening hypocalcemia. Patients must undergo a 'washout period' (usually 4 weeks) when switching from Cinacalcet to Etelcalcetide.
Cinacalcet is a strong inhibitor of the liver enzyme CYP2D6. This means it can slow down the breakdown of other drugs that rely on this enzyme, leading to toxic levels of those drugs in the blood. Examples include:
There is one primary absolute contraindication for the initiation of Cinacalcet therapy:
Cinacalcet is currently classified as a medication with limited human data regarding pregnancy. In animal studies (rats and rabbits), no evidence of teratogenicity (birth defects) was found at doses significantly higher than the human equivalent. However, in pregnant rats, the drug did cross the placental barrier and caused a decrease in fetal body weight and lower serum calcium levels in the offspring.
Because of the lack of well-controlled studies in humans, Cinacalcet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally not used in fertility treatments. If you become pregnant while taking Cinacalcet, notify your doctor immediately.
It is not known whether Cinacalcet is excreted in human milk. Animal studies have shown that Cinacalcet is excreted in the milk of lactating rats, with a high milk-to-plasma ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (specifically severe hypocalcemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Cinacalcet is an allosteric modulator of the calcium-sensing receptor (CaSR). The CaSR is a Class C G-protein coupled receptor. Its primary role in the parathyroid gland is to sense changes in extracellular ionized calcium and regulate the secretion of parathyroid hormone (PTH) accordingly.
Cinacalcet binds to the transmembrane domain of the CaSR. This binding does not activate the receptor directly but rather increases the sensitivity of the receptor to the calcium already present in the blood. By shifting the concentration-response curve for calcium to the left, Cinacalcet allows the receptor to be activated at lower calcium concentrations. Once activated, the receptor triggers an intracellular signaling cascade (involving phospholipase C and increased intracellular calcium) that inhibits the exocytosis of PTH from the chief cells of the parathyroid gland.
The effect of Cinacalcet on PTH levels is rapid. Following a single oral dose, PTH levels begin to fall within 30 minutes, reaching a nadir (lowest point) approximately 2 to 4 hours post-dose. Serum calcium levels follow this decline, though more slowly, typically reaching a nadir 12 to 24 hours after administration. There is a clear dose-response relationship; higher doses lead to greater suppression of PTH. Tolerance does not typically develop, meaning the drug remains effective over long-term use provided the underlying disease state is managed.
Common questions about Sensipar
Cinacalcet is primarily used to treat secondary hyperparathyroidism in adult patients with chronic kidney disease who are on dialysis. It is also used to lower high calcium levels in patients with parathyroid cancer or primary hyperparathyroidism who cannot have surgery. By reducing parathyroid hormone (PTH) levels, it helps prevent bone disease and other complications associated with mineral imbalances. It works by making the parathyroid gland more sensitive to the calcium already in your blood. Your doctor will determine the appropriate use based on your specific lab results and medical history.
The most common side effects reported by patients taking Cinacalcet are nausea and vomiting, which occur in a significant number of users. These symptoms are often most intense when starting the medication or during a dose increase. Other frequent side effects include diarrhea, muscle aches (myalgia), and dizziness. Low blood calcium, or hypocalcemia, is also a common and serious side effect that requires regular monitoring. Taking the medication with food is a widely recommended strategy to help reduce the gastrointestinal upset associated with the drug.
There is no known direct chemical interaction between alcohol and Cinacalcet, but caution is advised. Alcohol can contribute to dehydration and may worsen side effects like dizziness and nausea. Additionally, heavy alcohol use can interfere with the management of electrolytes and minerals, which is the primary goal of Cinacalcet therapy. It is best to discuss your alcohol consumption with your healthcare provider to ensure it does not interfere with your treatment plan. Moderation is generally recommended to avoid complicating your kidney or parathyroid condition.
The safety of Cinacalcet during pregnancy has not been well-established in humans, as there are no comprehensive clinical trials in pregnant women. Animal studies have shown that the drug can cross the placenta and potentially affect the calcium levels of the fetus. Because calcium is crucial for fetal development, Cinacalcet should only be used if the potential benefit to the mother outweighs the potential risk to the baby. Women who are pregnant or planning to become pregnant should consult their specialist immediately. Breastfeeding is also generally discouraged while taking this medication due to the risk of low calcium in the infant.
Cinacalcet begins to lower parathyroid hormone (PTH) levels very quickly, often within 30 minutes to 2 hours after the first dose. However, it takes longer for the full clinical effect on calcium and phosphorus levels to stabilize. Doctors usually wait 2 to 4 weeks after starting the medication or changing the dose before checking blood levels to see the full impact. You may not 'feel' the medication working, as the conditions it treats are often asymptomatic. Consistent use and regular blood tests are necessary to confirm the medication is achieving the desired results.
You should never stop taking Cinacalcet suddenly without consulting your healthcare provider. Abruptly discontinuing the medication can cause your parathyroid hormone (PTH) and blood calcium levels to rise rapidly, which can lead to complications. If you need to stop the medication due to side effects or a change in treatment, your doctor will likely provide a plan to monitor your blood work closely. In some cases, your dose may need to be tapered down rather than stopped all at once. Always follow your medical team's instructions regarding the discontinuation of this drug.
If you miss a dose of Cinacalcet, take it as soon as you remember, unless it is nearly time for your next scheduled dose. If you are within a few hours of your next dose, skip the missed one and continue with your regular schedule. Do not take two doses at the same time to make up for the one you missed, as this increases the risk of side effects like severe nausea or low calcium. If you miss multiple doses in a row, contact your doctor, as they may want to check your calcium levels. Consistency is key to maintaining stable mineral levels in your body.
Weight gain is not a commonly reported side effect of Cinacalcet in clinical trials. In fact, because the medication frequently causes nausea and vomiting, some patients may actually experience a decrease in appetite or slight weight loss when they first start the drug. If you notice significant or rapid changes in your weight while taking Cinacalcet, it is more likely related to your underlying kidney condition or changes in fluid balance. You should report any sudden weight changes or swelling (edema) to your healthcare provider. They can help determine if the change is related to your medication or your overall health status.
Cinacalcet can interact with several other medications, so it is vital to provide your doctor with a full list of everything you take. It is a strong inhibitor of the CYP2D6 enzyme, which means it can increase the levels of certain antidepressants, antipsychotics, and heart rhythm medications. Conversely, other drugs that inhibit the CYP3A4 enzyme can increase the levels of Cinacalcet in your body. It is also important not to take Cinacalcet with other calcimimetic drugs like Etelcalcetide. Your pharmacist and doctor will check for these interactions to ensure your combination of medications is safe.
Yes, Cinacalcet is available as a generic medication, which is typically more cost-effective than the brand-name version, Sensipar. Generic versions have been approved by the FDA and are required to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. The availability of generics has made this important treatment more accessible to patients with chronic kidney disease. When filling your prescription, you may receive the generic version unless your doctor specifically requests the brand name. Both versions are subject to the same rigorous quality and safety standards.
Other drugs with the same active ingredient (Cinacalcet)
> Warning: Stop taking Cinacalcet and call your doctor immediately or seek emergency care if you experience any of the following symptoms of severe hypocalcemia:
As of 2026, there are no FDA black box warnings for Cinacalcet. However, the FDA has issued several 'Warnings and Precautions' regarding the risk of severe hypocalcemia, particularly in pediatric populations and patients with seizure disorders. The medication is contraindicated in patients whose serum calcium is below the lower limit of the normal range at the start of therapy.
Report any unusual symptoms, especially muscle cramps or heart palpitations, to your healthcare provider immediately. Regular blood tests are the only way to catch these side effects before they become dangerous.
Decreases in serum calcium can prolong the QT interval on an electrocardiogram (ECG). This can lead to a dangerous heart rhythm known as ventricular arrhythmia. Patients with 'Long QT Syndrome' or those taking other medications that affect the heart rhythm must be monitored with extreme care.
As mentioned previously, excessively low PTH levels (e.g., <100-150 pg/mL) can lead to adynamic bone disease, a condition where bone remodeling stops. This increases the risk of 'hungry bone syndrome' and fractures. If PTH levels fall below the target range, the dose of Cinacalcet must be reduced or discontinued.
There have been rare reports of gastrointestinal bleeding in patients taking calcimimetics, though a direct causal link is still being studied. Patients with a history of peptic ulcers should inform their doctor.
To ensure safety, the following monitoring schedule is typically employed:
Cinacalcet can cause dizziness or seizures in some patients. You should not drive or operate heavy machinery until you know how this medication affects you, especially during the first few weeks of treatment or after a dose increase.
There is no direct chemical interaction between alcohol and Cinacalcet. However, alcohol can cause dehydration and electrolyte imbalances, which may complicate the management of calcium levels. Furthermore, alcohol can worsen the nausea and dizziness associated with Cinacalcet. It is best to limit alcohol consumption while on this medication.
Do not stop taking Cinacalcet suddenly. Stopping the medication can cause a rapid 'rebound' increase in PTH and calcium levels, which can be dangerous. If the medication must be stopped, your doctor will provide a tapering schedule and monitor your blood work closely during the transition.
> Important: Discuss all your medical conditions, especially liver disease, heart rhythm problems, or a history of seizures, with your healthcare provider before starting Cinacalcet.
Drugs that inhibit the CYP3A4 enzyme can prevent the breakdown of Cinacalcet, leading to higher levels of Cinacalcet and an increased risk of side effects. Examples include:
Cinacalcet does not typically interfere with standard laboratory test methodologies. However, its physiological effect of lowering PTH and calcium will obviously be reflected in lab results. It is important that blood for PTH testing is drawn at a consistent time relative to your Cinacalcet dose (usually just before the next dose) to ensure accurate monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is necessary to avoid dangerous interactions.
There is no known cross-sensitivity between Cinacalcet and other major drug classes (like penicillins or sulfonamides). However, patients who have had a reaction to other calcimimetics (like Etelcalcetide) should be monitored closely for similar allergic responses, although the chemical structures of these two drugs are different.
> Important: Your healthcare provider will evaluate your complete medical history, including your latest blood work, before prescribing Cinacalcet. Always report any history of low calcium or seizures.
The safety and efficacy of Cinacalcet in pediatric patients have not been established for the treatment of secondary hyperparathyroidism or parathyroid carcinoma. Following the death of a 14-year-old patient in a clinical trial due to severe hypocalcemia, the FDA has been extremely cautious. While some pediatric trials have explored its use for rare mineral disorders, it is not standard practice and is considered 'off-label' and high-risk in most pediatric settings.
Clinical studies of Cinacalcet included a significant number of subjects aged 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, the elderly are more prone to polypharmacy (taking multiple medications), which increases the risk of CYP2D6-mediated drug interactions. Additionally, the risk of falls due to dizziness (a potential side effect) is a greater concern in this population.
Cinacalcet is specifically indicated for patients with end-stage renal disease (ESRD) on dialysis. No dosage adjustment is required based on the degree of renal impairment. It is important to note that Cinacalcet is not effectively removed by hemodialysis or peritoneal dialysis due to its high protein binding and large volume of distribution.
In patients with moderate to severe hepatic impairment, the half-life of Cinacalcet is prolonged and plasma levels are higher. Specifically, the AUC (total exposure) was 2.4 times higher in patients with moderate impairment and 4.2 times higher in those with severe impairment. Healthcare providers will monitor serum calcium and PTH levels even more frequently in these patients during dose titration.
> Important: Special populations require individualized medical assessment. Always inform your specialist about your pregnancy status or any history of liver disease.
| Parameter | Value |
|---|---|
| Bioavailability | 20-25% (Fasted), up to 81% (with high-fat meal) |
| Protein Binding | 93% to 97% |
| Half-life | 30 to 40 hours (Terminal) |
| Tmax | 2 to 6 hours |
| Metabolism | Hepatic (CYP3A4, 2D6, 1A2) |
| Excretion | Renal 80%, Fecal 15% |
Cinacalcet belongs to the therapeutic class of Calcimimetics. It is currently the only oral agent in this class. Its primary therapeutic area is Mineral and Bone Disorder (MBD) in the context of Chronic Kidney Disease. Related medications include Etelcalcetide (an intravenous calcimimetic) and various Vitamin D analogs like Calcitriol or Paricalcitol, though the latter work through a different mechanism (the Vitamin D receptor).